Tumor Institute Radiation Oncology Group

Tumor Institute Radiation Oncology Group The Tumor Institute Radiation Oncology Group (TIROG) is a team of radiation oncologists committed to care for cancer patients in the greater Seattle area.

TIROG is committed to providing world class radiation oncology care in your community. We are a group of 15 radiation oncologists, all board certified, all trained at prestigious academic institutions with the combined goal of providing compassionate and highly specialized cancer care. TIROG is one of the largest providers of radiation therapy on the west coast and the largest radiation oncology group in the Seattle area. We are the premier provider of radiation therapy from Edmonds to Burien and Ballard to Issaquah. TIROG physicians pioneered the first prostate brachytherapy procedures in the United States and continue training radiation oncologists around the country with our educational courses. TIROG physicians were the first in the US to utilize Calypso 'GPS for the Body' real-time localization technology. We are active in research and technological development while maintaining our primary goal of providing dedicated individualized patient care. Radiation Oncology is the medical field that specializes in treating cancer patients with radiation therapy. Radiation can be given as a curative treatment alone in some cases, or in combination with surgery and or chemotherapy. Radiation also can be used palliatively, ie to help control symptoms such as pain or to prevent fracture of bones involved with cancer. In certain specializes cases, radiation therapy is used for non-cancer treatment. These include arterio-venous malformations, trigeminal neuralgia, essential tremor, and treating other benign tumors. We as radiation oncologists work as part of the multi-disciplinary team along side medical oncologists (who deliver chemotherapy and hormonal threrapy), surgeons, and other care providers. Overall, about 60% of all cancer patients in the US will receive radiation as part of their cancer treatment. Our Providers

Todd A. Barnett, M.D. Robert Douglas, M.D. Stephen Eulau, M.D. Daniel Landis, M.D., Ph.D. Brian Lee, M.D., Ph.D. Skyler Lindsley, M.D. Christopher Loiselle, M.D. Timothy Mate, M.D. Vivek Mehta, M.D. Robert Meier, M.D. Astrid Morris, M.D. James Spiegel, M.D. Robert Takamiya, M.D. John Travaglini, M.D. Sandra Vermeulen, M.D. Skyler K. Lindsley, M.D.

Dr. Meier in the news - Cyberknife Prostate 5 year data! Treating cancer in 5 days: local research pushes therapy to for...
02/25/2019

Dr. Meier in the news - Cyberknife Prostate 5 year data!

Treating cancer in 5 days: local research pushes therapy to forefront, KOMO

SEATTLE-- Curing prostate cancer could be as simple as five days of treatment, with no hospital stay. A local doctor's research is now pushing the five day therapy called CyberKnife to the forefront. Seattle's Primo Kim was a candidate for the treatment, after learning his cancer was confined to the...

This week, hundreds of radiation oncologists from around the world gathered for the ASTRO (American Society for Radiatio...
10/25/2018

This week, hundreds of radiation oncologists from around the world gathered for the ASTRO (American Society for Radiation Oncology) conference in San Antonio. The plenary session was the presentation of an amazing study. This study showed that treating patients with 3 or less metastatic tumors with SBRT such as Cyberknife doubled their overall survival.

We have seen many recent studies showing the benefit to high-dose short-course intense radiation therapy such as Cyberknife (SBRT = stereotactic body radiation therapy). However this is one of the most impressive studies to date.

We have treated patients in this way for over 10 years at the Swedish Radiosurgery Center. It is rewarding to see the progression of these clinical trials and now, after many years of personally seeing positive results, the presentation of long-term data.

In the first randomized, phase II clinical trial of its kind, researchers have shown that an aggressive form of high-precision radiation therapy can greatly increase how long oligometastatic patients live and doubles how long they live without cancer. The findings will be presented in a news briefin...

02/20/2017

We are excited and proud to report the remarkable 5-year data for treating Prostate Cancer with the Cyberknife. Dr. Robert Meier, the principal investigator of this national trial, has presented the data at ASTRO in Boston in September 2016 and the full publication will be forthcoming... Thank You Accuray for your support!

Dr. Stephen Eulau, one of our Prostate Cancer specialists, at Swedish Cancer Institutehttps://www.youtube.com/watch?v=6S...
10/26/2016

Dr. Stephen Eulau, one of our Prostate Cancer specialists, at Swedish Cancer Institute

https://www.youtube.com/watch?v=6S6AdPrTmVw

Dr. Stephen M. Eulau is the medical director of Seattle Prostate Institute and a radiation oncologist at Swedish Medical Center. Dr. Eulau meets with individ...

10/26/2016

Our Physicians, Dr. Chris Loiselle and Dr. Sandra Vermeulen, featured on the Eleckta Gamma Knife website - a good place for Q&A regarding Gamma Knife radiosurgery

http://gammaknife.com/learn-form-patients-medical-experts/

More studies have been done on Gamma Knife® than all other stereotactic radiosurgery systems combined. Over 300 centers worldwide prefer Gamma Knife for brain radiosurgery.

A look at cutting edge treatment for prostate cancer featuring our very own Dr. Robert Meier.
10/05/2016

A look at cutting edge treatment for prostate cancer featuring our very own Dr. Robert Meier.

Dr. Robert Meier and CyberKnife® patient Mike “Bing” Crosby take to the air to discuss CyberKnife System treatments for low- to intermediate-risk prostate ca...

10/05/2016

Address

First Hill Campus 1221 Madison St First Floor
Seattle, WA
98104

Alerts

Be the first to know and let us send you an email when Tumor Institute Radiation Oncology Group posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram

Category